A new £6.2 million investment will help bring advanced neurotechnology into patient care through a partnership between Newcastle University, Newcastle upon Tyne Hospitals NHS Foundation Trust and the Advanced Research and Invention Agency.
The funding will support more clinical trials and new treatments at the National Centre for Neurotechnology and Neurorestoration (NCNN), which was established by the NHS in 2025. It is the first UK centre dedicated to speeding up the use of technologies that interact with the brain and nervous system.
From promising technology to patient care
The centre works with technologies including brain-computer interfaces, implants, neuromodulation and neuroprosthetics. These could help people affected by Parkinson’s disease, epilepsy, motor neurone disease, spinal cord injury, severe pain and difficulties with movement, communication, memory or concentration.
The investment will expand clinical facilities and grow a specialist workforce of clinical, technical and research staff. It will also support training and multi-site studies involving other NHS organisations and research centres, potentially giving more patients access to innovative treatments.
Based at Newcastle Hospitals, the centre brings clinicians, researchers, industry partners and patients together in a hospital setting. The aim is to make it easier for promising discoveries to move from development and testing into everyday healthcare.
Why it matters for Britain
The project will create specialist roles and strengthen neurotechnology expertise in the UK. By involving more NHS organisations in studies, it could also widen access to emerging treatments for people living with serious neurological conditions.




